

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

SAB Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☒ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Vivo Opportunity Fund Holdings, L.P.

Check the appropriate box if a member of a Group (see instructions)

☐ (a)

☒ (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares	5	Sole Voting Power
Beneficially Owned by Each Reporting Person With:	22,637,108.00	Shared Voting Power
	6	0.00
		Sole Dispositive Power
	7	22,637,108.00
		Shared Dispositive Power
	8	0.00
	Aggregate Amount Beneficially Owned by Each Reporting Person	
	9	22,637,108.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	10	☐
	Percent of class represented by amount in row (9)	
	11	9.99 %
	Type of Reporting Person (See Instructions)	
	12	PN

Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 6,632,508 shares of common stock, par value \$0.0001 per share (the "Common Stock") of SAB Biotherapeutics, Inc. (the "Issuer"), (ii) 446,000 shares of Common Stock issuable upon conversion of 4,460 shares of the Issuer's Series B Preferred Stock, par value \$0.0001 per share (the "Series B Preferred Stock") convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons	
1	Vivo Opportunity, LLC	
	Check the appropriate box if a member of a Group (see instructions)	
2	☐ (a)	
	☒ (b)	
3	Sec Use Only	
	Citizenship or Place of Organization	
4	DELAWARE	
Number of Shares	5	Sole Voting Power
Beneficially Owned by Each	22,637,108.00	
	6	Shared Voting Power

Reporting Person With:	0.00
	Sole Dispositive Power
7	22,637,108.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	22,637,108.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	9.99 %
12	Type of Reporting Person (See Instructions)
	OO

Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 6,632,508 shares of Common Stock of the Issuer, (ii) 446,000 shares of Common Stock issuable upon conversion of 4,460 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Vivo Opportunity Cayman Fund, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:	Sole Voting Power
5	2,286,301.00
	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	2,286,301.00
	Shared Dispositive Power
8	

	0.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	2,286,301.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10	☐
	Percent of class represented by amount in row (9)
11	9.99 %
	Type of Reporting Person (See Instructions)
12	PN

Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 667,401 shares of Common Stock of the Issuer, (ii) 47,500 shares of Common Stock issuable upon conversion of 475 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	Vivo Opportunity Cayman, LLC
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☒ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	CAYMAN ISLANDS
	Sole Voting Power
5	2,286,301.00
Number of	Shared Voting Power
Shares	6
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	7
Reporting	2,286,301.00
Person	Shared Dispositive
With:	8
	Power
	0.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	2,286,301.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

11 9.99 %

Type of Reporting Person (See Instructions)

12 OO

Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 667,401 shares of Common Stock of the Issuer, (ii) 47,500 shares of Common Stock issuable upon conversion of 475 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.

SCHEDULE 13G

Item 1.

Name of issuer:

(a) SAB Biotherapeutics, Inc.

Address of issuer's principal executive offices:

(b) 777 W 41st St, Suite 401, Miami Beach, FL 33140

Item 2.

Name of person filing:

(a) Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC

Address or principal business office or, if none, residence:

(b) 192 Lytton Avenue, Palo Alto, CA 94301

Citizenship:

(c) Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership. Vivo Opportunity, LLC is a Delaware limited liability company. Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership. Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.

Title of class of securities:

(d) Common Stock, par value \$0.0001 per share

(e) CUSIP No.:

Item 4. Ownership

(a) Amount beneficially owned:

Vivo Opportunity, LLC may be deemed to beneficially own an aggregate of 22,637,108 shares of the Issuer's securities, consisting of (i) 6,632,508 shares of Common Stock of the Issuer, (ii) 446,000 shares of Common Stock issuable upon conversion of 4,460 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC may be deemed to beneficially own an aggregate

of 2,286,301 shares of the Issuer's securities, consisting of (i) 667,401 shares of Common Stock of the Issuer, (ii) 47,500 shares of Common Stock issuable upon conversion of 475 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement. These securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in this Item 4 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.

Percent of class:

(b) Vivo Opportunity Fund Holdings, L.P.: 9.99% Vivo Opportunity, LLC: 9.99% Vivo Opportunity Cayman Fund, L.P.: 9.99% Vivo Opportunity Cayman, LLC: 9.99% %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Vivo Opportunity Fund Holdings, L.P.: 22,637,108 shares Vivo Opportunity, LLC: 22,637,108 shares Vivo Opportunity Cayman Fund, L.P.: 2,286,301 shares Vivo Opportunity Cayman, LLC: 2,286,301 shares

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

Vivo Opportunity Fund Holdings, L.P.: 22,637,108 shares Vivo Opportunity, LLC: 22,637,108 shares Vivo Opportunity Cayman Fund, L.P.: 2,286,301 shares Vivo Opportunity Cayman, LLC: 2,286,301 shares

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Opportunity Fund Holdings, L.P.

Signature: /s/ Kevin Dai

Name/Title: Kevin Dai/Managing Member of Vivo

Opportunity, LLC, General Partner

Date: 08/14/2026

Vivo Opportunity, LLC

Signature: /s/ Kevin Dai

Name/Title: Kevin Dai/Managing Member

Date: 08/14/2026

Vivo Opportunity Cayman Fund, L.P.

Signature: /s/ Kevin Dai

Name/Title: Kevin Dai/Managing Member of Vivo
Opportunity Cayman, LLC, General Partner

Date: 08/14/2026

Vivo Opportunity Cayman, LLC

Signature: /s/ Kevin Dai

Name/Title: Kevin Dai/Managing Member

Date: 08/14/2026